If you enjoy this content, please share it with a colleague
RELATED CONTENT
An interview with A. M. Niser Syed, M.D., medical director, radiation oncology and endocurietherapy, MemorialCare Cancer ...
In recent years, intraoperative radiation therapy (IORT) has been growing in acceptance in the U.S. as an alternative to traditional external beam radiation therapy (EBRT) for patients with early-stage breast cancer. For patients meeting appropriate selection criteria, the benefits are clear — shorter treatment times, added convenience, lower costs and fewer complications.[1, 2]
iCAD Inc. presented updated clinical data, hosted in-booth clinician presentations and showcased the latest in radiation technology at the American Society for Radiation Oncology (ASTRO) meeting in San Antonio, Texas, Oct. 18-21, 2015.
The unfortunate reality of living with cancer is that oftentimes, the treatment can be just as much of a burden for patients as the disease itself.
The radiation therapy market, hit hard in 2009 by the recession, saw a sharp decline in purchasing from which it has slowly recovered. During the last five years the market has been steadily growing, with capital equipment budgets for radiation oncology sites increasing. However, it has only been within the last year that equipment purchases for radiation therapy have leveled out. Purchasing decisions today are driven by two main factors: advancements in technology, including more targeted treatment, multifunctional capabilities and improved patient safety; and the evolving reimbursement model, which weighs patient outcomes and the quality of care delivered more heavily.
iCAD Inc. has announced a strategic alliance with DermEbx to offer the Xoft Axxent Electronic Brachytherapy System to treat non-melanoma skin cancer (NMSC) throughout the DermEbx network of dermatology centers.
iCAD Inc. has entered into strategic distribution agreements for its Xoft Axxent Electronic Brachytherapy System with Chindex Medical Limited in China and with Medvio in Russia. The company also announced that the first breast cancer patient was treated with intraoperative radiation therapy (IORT) using the Xoft system in Taiwan.
December 15, 2011 – Diablo Valley Oncology, an oncology practice in the San Francisco East Bay, recently administered its first breast intraoperative radiation treatment (IORT) using the Xoft Axxent eBx electronic brachytherapy system at Aspen Surgical in Walnut Creek.
Intraoperative radiation therapy (IORT) for breast cancer is emerging as a newer alternative to whole-breast radiation therapy and accelerated partial breast irradiation (APBI).
April 14, 2011 – A class I recall has been issued for the Xoft Axxent Flexishield Mini because the product may shed particles of tungsten that can be mistaken for suspicious breast calcifications during follow up X-rays or scans.